Waters, NIBRT Partner to Grow Knowledge of Large-Molecule Characterization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Waters, NIBRT Partner to Grow Knowledge of Large-Molecule Characterization


ePT--the Electronic Newsletter of Pharmaceutical Technology

The National Institute for Bioprocessing Research and Training (NIBRT) in Ireland and Waters are partnering on training and research to increase large-molecule characterization capacity and knowledge, according to an NIBRT press release.

The two organizations established the Complete Product and Processing Characterization Facility for hands-on laboratory-based scientific training and retraining of “fit-for-purpose” biopharmaceutical analysis, including protein and peptide characterization. The goal of the facility is to provide comprehensive training of industry and governmental technicians and scientists in an effort to develop advanced biotherapeutic characterization Training on US and European drug regulations will also be offered. Finally, the partnership establishes NIBRT as a Waters Center of Innovation in the area of glycobiology research.

“Ireland is a leading location globally for the development and manufacture of complex biopharmaceutical drugs. This is due in large part to a sustained commitment to quality and compliance with the highest regulatory standards,” said NIBRT’s Interim Director Prof. Ian Marison.

“Through this lab and other collaborations, Waters will work with industry to improve the development of biopharmaceuticals and inform governments on the types of regulations that should be put in place,” said Mike Harrington, Waters vice-president, European Operations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here